159 related articles for article (PubMed ID: 29130630)
1. A structure-based strategy toward the development of novel candidates for antimycobacterial activity: Synthesis, biological evaluation, and docking study.
Li L; Jin Y; Wang B; Yang Z; Liu M; Guo H; Zhang J; Lu Y
Chem Biol Drug Des; 2018 Mar; 91(3):769-780. PubMed ID: 29130630
[TBL] [Abstract][Full Text] [Related]
2. Confronting Tuberculosis: A Synthetic Quinoline-Isonicotinic Acid Hydrazide Hybrid Compound as a Potent Lead Molecule Against
Vadankula GR; Nilkanth VV; Rizvi A; Yandrapally S; Agarwal A; Chirra H; Biswas R; Arifuddin M; Nema V; Mallika A; Mande SC; Banerjee S
ACS Infect Dis; 2024 Jun; 10(6):2288-2302. PubMed ID: 38717380
[TBL] [Abstract][Full Text] [Related]
3. New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity.
Nayak N; Ramprasad J; Dalimba U
Bioorg Med Chem Lett; 2015 Dec; 25(23):5540-5. PubMed ID: 26520663
[TBL] [Abstract][Full Text] [Related]
4. Structure elaboration of isoniazid: synthesis, in silico molecular docking and antimycobacterial activity of isoniazid-pyrimidine conjugates.
Kaur H; Singh L; Chibale K; Singh K
Mol Divers; 2020 Nov; 24(4):949-955. PubMed ID: 31691051
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases.
Narender M; Jaswanth S B; Umasankar K; Malathi J; Raghuram Reddy A; Umadevi KR; Dusthackeer AVN; Venkat Rao K; Raghuram R A
Bioorg Med Chem Lett; 2016 Feb; 26(3):836-840. PubMed ID: 26755393
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents.
Balaji NV; Hari Babu B; Subbaraju GV; Purna Nagasree K; Murali Krishna Kumar M
Bioorg Med Chem Lett; 2017 Jan; 27(1):11-15. PubMed ID: 27894872
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.
Shakya N; Srivastav NC; Bhavanam S; Tse C; Desroches N; Agrawal B; Kunimoto DY; Kumar R
Bioorg Med Chem; 2012 Jul; 20(13):4088-97. PubMed ID: 22664188
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and antimycobacterial activity of benzoxazinone derivatives and open-ring analogues: Preliminary data and computational analysis.
Zampieri D; Mamolo MG; Filingeri J; Fortuna S; De Logu A; Sanna A; Zanon D
Bioorg Med Chem Lett; 2019 Sep; 29(17):2468-2474. PubMed ID: 31350124
[TBL] [Abstract][Full Text] [Related]
11. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, In silico Molecular Docking and Pharmacokinetic Studies, In vitro Antimycobacterial and Antimicrobial Studies of New Imidozolones Clubbed with Thiazolidinedione.
Khan IH; Patel NB; Patel VM
Curr Comput Aided Drug Des; 2018; 14(4):269-283. PubMed ID: 29766819
[TBL] [Abstract][Full Text] [Related]
14. Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.
Dongamanti A; Aamate VK; Devulapally MG; Gundu S; Balabadra S; Manga V; Yogeeswari P; Sriram D; Balasubramanian S
Mol Divers; 2017 Nov; 21(4):999-1010. PubMed ID: 28840414
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation.
Kumar D; Beena ; Khare G; Kidwai S; Tyagi AK; Singh R; Rawat DS
Eur J Med Chem; 2014 Jun; 81():301-13. PubMed ID: 24852277
[TBL] [Abstract][Full Text] [Related]
16. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
Dinakaran M; Senthilkumar P; Yogeeswari P; China A; Nagaraja V; Sriram D
Bioorg Med Chem; 2008 Mar; 16(6):3408-18. PubMed ID: 18304818
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H-1,2,3-triazole-isatin hybrids.
Xu Z; Zhang S; Song X; Qiang M; Lv Z
Bioorg Med Chem Lett; 2017 Aug; 27(16):3643-3646. PubMed ID: 28720502
[TBL] [Abstract][Full Text] [Related]
18. Quinoline derivatives as potential anti-tubercular agents: Synthesis, molecular docking and mechanism of action.
Liu CX; Zhao X; Wang L; Yang ZC
Microb Pathog; 2022 Apr; 165():105507. PubMed ID: 35354076
[TBL] [Abstract][Full Text] [Related]
19. Hybrids of thienopyrimidinones and thiouracils as anti-tubercular agents: SAR and docking studies.
Pisal MM; Nawale LU; Patil MD; Bhansali SG; Gajbhiye JM; Sarkar D; Chavan SP; Borate HB
Eur J Med Chem; 2017 Feb; 127():459-469. PubMed ID: 28103537
[TBL] [Abstract][Full Text] [Related]
20. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
